THE FORUM
For Collaborative Research℠

Advancing Therapeutic Development for COVID-19 Treatment 1

Washington, DC

Thursday, November 2, 2023

Berkeley Public Health

Introductory Remarks

Veronica Miller, *Forum for Collaborative Research*

Forum Overview

Overview of The Forum

- **What:** a platform for ongoing multi-stakeholder dialogue to identify barriers, prioritize research and identify solutions to accelerate therapeutic development for various diseases
- **How:** provide a neutral, independent, safe space for discussion and deliberation across stakeholder groups
  - Focus on developing consensus, increasing synergy and collaboration, and reducing duplication and uncertainty
  - Ongoing working group activity throughout the year anchored by larger project events
  - Active & engaged participation



The Forum's Concept

THE FORUM For Collaborative Research℠



Increase Efficiency

- Enhanced clarity
- Innovation
- Collaboration

Decrease Uncertainty

- Redundancy
- Development time
- Risk

Forum Operating Principles

- Independent and neutral venue
  - Ongoing multi-stakeholder dialogue
  - Each stakeholder group has an equal voice
- Facilitate best science-based decisions, in real time
  - Break down inefficiencies and redundancy
  - Increase clarity, collaboration and innovation
  - Benefit to whole field, especially patients

Forum = Safe Space

- Closed meeting
  - No marketing
  - No press
- Bring your expertise
  - Leave your “hat” at the door

Rules of the Room and Zoom

THE FORUM
For Collaborative Research℠

What's said in the room, stays in the room

What's said in the room, is not for attribution

Let the science speak

Active participation

Forum Team

THE FORUM
For Collaborative Research℠

- Veronica Miller – Director
- Christopher Berry – Events Manager
- Donnice Butler – Senior Administrative Assistant
- Nicholas Murdock – Research Associate
- Mitchell Leus – Research Associate
- **Shilpa Mitra – Research Associate**
- Logan Donaldson – Research Associate
- Sehyr Khan – Research Associate
- Azza Karrar – Senior Research Associate
- Alicia Jellinek – Program Financial Analyst
- Chris Hoffman – IT and Operational Director
- Margot Yann – Lead Data Scientist
- Zachary Rooney – Research Associate
- Sammy Berman – Research Data Analyst
- Robin Schaefer – Post-Doctoral Researcher

- **Jeffrey S. Murray – Program Advisor**
- John Sninsky – Program Advisor

- Alessi Ayvaz, Undergraduate Student Researcher

Project Overview and Agenda

Overview of the COVID-19 Project

- Given current high rates of natural and vaccine-mediated immunity, a trial endpoint relying only on hospitalization and/or death may no longer be practical
- There remains populations with unmet medical need for broadly active therapeutics that can prevent and treat COVID-19
- Series of meetings will convene stakeholders to strategize on establishing acceptable trial designs, control arms, and clinical and/or surrogate virologic endpoints for future COVID-19 therapeutic drug development

Part 1: Meeting Agenda

- Session 1: Characterizing Risk Factors for Severe COVID-19 to Inform Participant Eligibility Criteria for Enrollment
  - Part A: Define patient populations based on risk of progression to severe COVID-19 and describe baseline risk factors
  - Part B: Ethical considerations for non-hospitalized patients with COVID-19
- Session 2: Possible Trial Endpoints and Medically Attended Visits
  - Medically Attended Visits (MAVs): Is it Time to Expand the Primary Endpoint for Trials in Participants with Mild-to-Moderate COVID-19?